Oaktree Fund Advisors LLC Makes New $949,000 Investment in Mesoblast Limited (NASDAQ:MESO)

Oaktree Fund Advisors LLC acquired a new stake in shares of Mesoblast Limited (NASDAQ:MESO) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 47,909 shares of the company’s stock, valued at approximately $949,000. Mesoblast accounts for 1.6% of Oaktree Fund Advisors LLC’s investment portfolio, making the stock its 18th largest holding.

A number of other institutional investors and hedge funds also recently made changes to their positions in MESO. Oaktree Capital Management LP acquired a new position in Mesoblast during the 4th quarter worth approximately $3,556,000. Strategic Financial Concepts LLC acquired a new stake in Mesoblast in the fourth quarter valued at approximately $2,744,000. Jane Street Group LLC increased its holdings in shares of Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after acquiring an additional 26,959 shares in the last quarter. Fi3 FINANCIAL ADVISORS LLC raised its position in shares of Mesoblast by 75.2% during the fourth quarter. Fi3 FINANCIAL ADVISORS LLC now owns 36,625 shares of the company’s stock worth $725,000 after purchasing an additional 15,725 shares during the period. Finally, Clayton Financial Group LLC bought a new position in shares of Mesoblast in the 4th quarter worth $275,000. Institutional investors own 1.43% of the company’s stock.

Mesoblast Price Performance

MESO opened at $12.11 on Friday. Mesoblast Limited has a 1 year low of $4.60 and a 1 year high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average price is $16.31 and its two-hundred day moving average price is $13.16.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Cantor Fitzgerald upgraded shares of Mesoblast to a “strong-buy” rating in a research note on Tuesday, March 4th. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Mesoblast has a consensus rating of “Moderate Buy” and an average price target of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.